PD-L1 in systemic immunity: unraveling its contribution to PD-1/PD-L1 blockade immunotherapy
| dc.contributor.author | Bocanegra Gondán, Ana Isabel | |
| dc.contributor.author | Blanco, Ester | |
| dc.contributor.author | Fernández Hinojal, Gonzalo | |
| dc.contributor.author | Chocarro de Erauso, Luisa | |
| dc.contributor.author | Zuazo Ibarra, Miren | |
| dc.contributor.department | Ciencias de la Salud | es_ES |
| dc.contributor.department | Osasun Zientziak | eu |
| dc.contributor.funder | Gobierno de Navarra / Nafarroako Gobernua | es |
| dc.date.accessioned | 2021-02-04T12:24:47Z | |
| dc.date.available | 2021-02-04T12:24:47Z | |
| dc.date.issued | 2020 | |
| dc.description.abstract | The use of monoclonal antibodies targeting PD-1/PD-L1 axis completely changed anticancer treatment strategies. However, despite the significant improvement in overall survival and progression-free survival of patients undergoing these immunotherapy treatments, the only clinically accepted biomarker with some prediction capabilities for the outcome of the treatment is PD-L1 expression in tumor biopsies. Nevertheless, even when having PD-L1-positive tumors, numerous patients do not respond to these treatments. Considering the high cost of these therapies and the risk of immune-related adverse events during therapy, it is necessary to identify additional biomarkers that would facilitate stratifying patients in potential responders and non-responders before the start of immunotherapies. Here, we review the utility of PD-L1 expression not only in tumor cells but in immune system cells and their influence on the antitumor activity of immune cell subsets. | en |
| dc.description.sponsorship | The Oncoimmunology group is funded by Asociación Española Contra el Cáncer, (AECC PROYE16001ESCO); Instituto de Salud Carlos III, Spain, (FIS grant PI17/02119); and a 'Precipita' Crowdfunding grant (FECYT), no grant number; Government of Navarre grant (BMED 050-2019); Independent Clinical Research Projects Call (Instituto de Salud Carlos III, Spain; TRANSPOCART); Proyectos estratégicos I+D, Departamento de Industria, Gobierno de Navarra (DESCARTHES). | en |
| dc.format.extent | 17 p. | |
| dc.format.mimetype | application/pdf | en |
| dc.identifier.doi | 10.3390/ijms21165918 | |
| dc.identifier.issn | 1422-0067 (Electronic) | |
| dc.identifier.uri | https://academica-e.unavarra.es/handle/2454/39151 | |
| dc.language.iso | eng | en |
| dc.publisher | MDPI | en |
| dc.relation.ispartof | International Journal of Molecular Sciences, 2020, 21(16), 5918 | en |
| dc.relation.publisherversion | https://doi.org/10.3390/ijms21165918 | |
| dc.rights | © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. | en |
| dc.rights.accessRights | info:eu-repo/semantics/openAccess | |
| dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
| dc.subject | PD-L1 | en |
| dc.subject | Immunotherapy | en |
| dc.subject | Immune | en |
| dc.subject | Checkpoint inhibition | en |
| dc.subject | Systemic myeloid subsets | en |
| dc.subject | Liquid biopsy | en |
| dc.subject | Biomarkers | en |
| dc.title | PD-L1 in systemic immunity: unraveling its contribution to PD-1/PD-L1 blockade immunotherapy | en |
| dc.type | info:eu-repo/semantics/article | |
| dc.type.version | info:eu-repo/semantics/publishedVersion | |
| dspace.entity.type | Publication | |
| relation.isAuthorOfPublication | fe5c362e-3c0c-4edb-aa2e-0de27c815ad2 | |
| relation.isAuthorOfPublication | 193d800d-c38c-4627-b9d8-d29435d8214c | |
| relation.isAuthorOfPublication.latestForDiscovery | fe5c362e-3c0c-4edb-aa2e-0de27c815ad2 |